Pacira BioSciences, Inc.
Health
Performance
3.2
Risk
Sell
Buy
Curious about the Scores? Learn more.

Pacira BioSciences, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

24.06.2026
Calmer waters ahead. Risk signals cooling off.
23.06.2026
Barely upright. Still chaotic, but slowly finding some balance.
11.01.2026
Momentum tanked. Clearly underperforming.
01.01.2026
Climbing out. Risks fading, but not out of the woods.
PCRX
Pacira BioSciences, Inc.
25.59
-0.74%
3.2
Sell
Buy
Pacira BioSciences, Inc.

Pacira BioSciences, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Pacira BioSciences, Inc. do? Business model and key facts

Get the full picture of Pacira BioSciences, Inc.: what it builds, where it operates, and how it makes money.

Pacira BioSciences, Inc. Profile

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees (FY): 825

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.

shop
Company facts
Frank D. Lee
CEO
825
Employees worldwide
shop
Performance
14.09%
Last 12 months
-55.93%
Last 5 years
shop
Growth
$726.41M
Revenue year
$7.03M
Net income
shop
Valuation
$1.01B
Market Cap
161.75
Price/Earnings Ratio

Stocks related to Pacira BioSciences, Inc.

Selected based on industry alignment and relative market positioning.

CRON
Cronos Group Inc.
2.78
-0.71%
5.8
Sell
Buy
Cronos Group Inc.
COLL
Collegium Pharmaceutical, Inc.
34.72
-3.15%
4.6
Sell
Buy
Collegium Pharmaceutical, Inc.
ALVO
Alvotech
3.19
-9.38%
6.8
Sell
Buy
Alvotech
GUD.TO
Knight Therapeutics Inc.
9.68
-2.91%
3.1
Sell
Buy
Knight Therapeutics Inc.
AMPH
Amphastar Pharmaceuticals, Inc.
19.30
-1.48%
7.5
Sell
Buy
Amphastar Pharmaceuticals, Inc.

Events and news impacting Pacira BioSciences, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Pacira BioSciences, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.